11/19
05:31 pm
autl
Systemic Lupus Erythematosus Clinical Trial Pipeline Gains Momentum as 120+ Key Companies at the Forefront | DelveInsight
Medium
Report
Systemic Lupus Erythematosus Clinical Trial Pipeline Gains Momentum as 120+ Key Companies at the Forefront | DelveInsight
11/19
05:31 pm
autl
Systemic Lupus Erythematosus Clinical Trial Pipeline Gains Momentum as 120+ Key Companies at the Forefront | DelveInsight
Medium
Report
Systemic Lupus Erythematosus Clinical Trial Pipeline Gains Momentum as 120+ Key Companies at the Forefront | DelveInsight
11/18
08:06 am
autl
Autolus Therapeutics plc (NASDAQ: AUTL) was upgraded by analysts at The Goldman Sachs Group, Inc. from a "neutral" rating to a "buy" rating. They now have a $7.60 price target on the stock, up previously from $7.00.
Medium
Report
Autolus Therapeutics plc (NASDAQ: AUTL) was upgraded by analysts at The Goldman Sachs Group, Inc. from a "neutral" rating to a "buy" rating. They now have a $7.60 price target on the stock, up previously from $7.00.
11/15
08:27 am
autl
Autolus Therapeutics Third Quarter 2024 Earnings: US$0.31 loss per share (vs US$0.26 loss in 3Q 2023) [Yahoo! Finance]
Medium
Report
Autolus Therapeutics Third Quarter 2024 Earnings: US$0.31 loss per share (vs US$0.26 loss in 3Q 2023) [Yahoo! Finance]
11/15
08:04 am
autl
Autolus Therapeutics plc (NASDAQ: AUTL) was upgraded by analysts at Redburn Atlantic from a "neutral" rating to a "buy" rating. They now have a $13.00 price target on the stock.
Medium
Report
Autolus Therapeutics plc (NASDAQ: AUTL) was upgraded by analysts at Redburn Atlantic from a "neutral" rating to a "buy" rating. They now have a $13.00 price target on the stock.
11/14
05:02 am
autl
BioNTech signs agreement to acquire Biotheus [Yahoo! Finance]
Medium
Report
BioNTech signs agreement to acquire Biotheus [Yahoo! Finance]
11/13
02:26 am
autl
Autolus Therapeutics PLC (AUTL) Q3 2024 Earnings Call Highlights: Strategic Advances and ... [Yahoo! Finance]
Low
Report
Autolus Therapeutics PLC (AUTL) Q3 2024 Earnings Call Highlights: Strategic Advances and ... [Yahoo! Finance]
11/12
07:00 am
autl
Autolus Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates
Medium
Report
Autolus Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates
11/11
01:07 pm
autl
Autolus secures FDA approval for CAR-T cell therapy use in ALL [Yahoo! Finance]
Low
Report
Autolus secures FDA approval for CAR-T cell therapy use in ALL [Yahoo! Finance]
11/11
08:10 am
autl
Autolus Therapeutics plc (NASDAQ: AUTL) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $9.00 price target on the stock.
High
Report
Autolus Therapeutics plc (NASDAQ: AUTL) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $9.00 price target on the stock.
11/11
07:33 am
autl
What To Expect From Autolus Therapeutics PLC (AUTL) Q3 2024 Earnings [Yahoo! Finance]
High
Report
What To Expect From Autolus Therapeutics PLC (AUTL) Q3 2024 Earnings [Yahoo! Finance]
11/8
04:30 pm
autl
Autolus Therapeutics Announces FDA Approval of AUCATZYL® (obecabtagene autoleucel – obe-cel) for adults with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) [Yahoo! Finance]
Medium
Report
Autolus Therapeutics Announces FDA Approval of AUCATZYL® (obecabtagene autoleucel – obe-cel) for adults with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) [Yahoo! Finance]
11/8
04:23 pm
autl
Autolus Therapeutics Announces FDA Approval of AUCATZYL® (obecabtagene autoleucel – obe-cel) for adults with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)
Medium
Report
Autolus Therapeutics Announces FDA Approval of AUCATZYL® (obecabtagene autoleucel – obe-cel) for adults with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)
11/5
09:00 am
autl
Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024 in One Oral Presentation and Three Poster Presentations
Low
Report
Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024 in One Oral Presentation and Three Poster Presentations
11/3
08:51 am
autl
Further weakness as Autolus Therapeutics (NASDAQ:AUTL) drops 21% this week, taking five-year losses to 71% [Yahoo! Finance]
Medium
Report
Further weakness as Autolus Therapeutics (NASDAQ:AUTL) drops 21% this week, taking five-year losses to 71% [Yahoo! Finance]
10/30
05:46 pm
autl
T-cell Malignancies Clinical Trial Pipeline Insights Featuring 70+ Companies | DelveInsight
High
Report
T-cell Malignancies Clinical Trial Pipeline Insights Featuring 70+ Companies | DelveInsight
10/30
05:46 pm
autl
T-cell Malignancies Clinical Trial Pipeline Insights Featuring 70+ Companies | DelveInsight
High
Report
T-cell Malignancies Clinical Trial Pipeline Insights Featuring 70+ Companies | DelveInsight
10/28
05:00 pm
autl
Autolus Therapeutics to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024
Medium
Report
Autolus Therapeutics to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024
10/16
09:00 am
autl
Autolus Therapeutics Presents Clinical Data Update at the 2024 Lymphoma, Leukemia & Myeloma Congress
Medium
Report
Autolus Therapeutics Presents Clinical Data Update at the 2024 Lymphoma, Leukemia & Myeloma Congress
9/23
08:42 am
autl
Interim Results for the Six Months Ended 30 June 2024
Medium
Report
Interim Results for the Six Months Ended 30 June 2024
9/19
05:31 pm
autl
Mantle Cell Lymphoma Clinical Trial Pipeline Insights Featuring 20+ Companies | DelveInsight
Medium
Report
Mantle Cell Lymphoma Clinical Trial Pipeline Insights Featuring 20+ Companies | DelveInsight
9/19
05:31 pm
autl
Mantle Cell Lymphoma Clinical Trial Pipeline Insights Featuring 20+ Companies | DelveInsight
Medium
Report
Mantle Cell Lymphoma Clinical Trial Pipeline Insights Featuring 20+ Companies | DelveInsight
9/19
07:00 am
autl
Autolus Therapeutics announces appointment of Matthias Will, M.D. as Chief Development Officer
Low
Report
Autolus Therapeutics announces appointment of Matthias Will, M.D. as Chief Development Officer
9/12
04:44 pm
autl
Autolus Therapeutics PLC (AUTL): Fast-Growing Penny Stock To Consider [Yahoo! Finance]
Low
Report
Autolus Therapeutics PLC (AUTL): Fast-Growing Penny Stock To Consider [Yahoo! Finance]
9/2
07:00 am
autl
Lucinda Crabtree joins Oxford Biomedica as Chief Financial Officer today
Medium
Report
Lucinda Crabtree joins Oxford Biomedica as Chief Financial Officer today